Cytokines and hormones that contribute to the positive association between fat and bone

Frontiers in Endocrinology

Volumn 5, Issue MAY, 2014, Pages

  Naot, Dorit ^a   Cornish, Jillian ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Adipokines; Adipose tissue; Fat bone association; Gastrointestinal peptides; Pancreatic hormones

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; AMYLIN; APELIN; CYTOKINE; FASTING INDUCED ADIPOSE FACTOR; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; HORMONE; INSULIN; LEPTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PREPTIN; SOMATOMEDIN B; SOMATOMEDIN C; UNCLASSIFIED DRUG; VASPIN;

BONE DENSITY; BONE MASS; BONE TURNOVER; FAT MASS; FEEDING; HUMAN; INSULIN LIKE ACTIVITY; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; REVIEW;

EID: 84905453700     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00070     Document Type: Review

References (127)

1. Reid IR. Fat and bone. Arch Biochem Biophys (2010) 503(1):20-7. doi: 10.1016/j.abb.2010.06.027
2. Sadie-Van Gijsen H, Crowther NJ, Hough FS, Ferris WF. The interrelationship between bone and fat: from cellular see-saw to endocrine reciprocity. Cell Mol Life Sci (2013) 70(13):2331-49. doi:10.1007/s00018-012-1211-2
3. Reid IR. Relationships between fat and bone. Osteoporos Int (2008) 19(5):595-606. doi:10.1007/s00198-007-0492-z
4. Reid IR. Relationships among body mass, its components, and bone. Bone (2002) 31(5):547-55. doi:10.1016/S8756-3282(02)00864-5
5. Sornay-Rendu E, Boutroy S, Vilayphiou N, Claustrat B, Chapurlat RD. In obese postmenopausal women, bone microarchitecture and strength are not commensurate to greater body weight: the Os des Femmes de Lyon (OFELY) study. J Bone Miner Res (2013) 28(7):1679-87. doi:10.1002/jbmr.1880
6. Wang MC, Bachrach LK, Van Loan M, Hudes M, Flegal KM, Crawford PB. The relative contributions of lean tissue mass and fat mass to bone density in young women. Bone (2005) 37(4):474-81. doi:10.1016/j.bone.2005.04.038
7. Dimitri P, Bishop N, Walsh JS, Eastell R. Obesity is a risk factor for fracture in children but is protective against fracture in adults: a paradox. Bone (2012) 50(2):457-66. doi:10.1016/j.bone.2011.05.011
8. Gilsanz V, Chalfant J, Mo AO, Lee DC, Dorey FJ, Mittelman SD. Reciprocal relations of subcutaneous and visceral fat to bone structure and strength. J Clin Endocrinol Metab (2009) 94(9):3387-93. doi:10.1210/jc.2008-2422
9. Compston J. Obesity and bone. Curr Osteoporos Rep (2013) 11(1):30-5. doi:10.1007/s11914-012-0127-y
10. Compston JE, Flahive J, Hosmer DW, Watts NB, Siris ES, Silverman S, et al. Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 29(2):487-93. doi:10.1002/jbmr.2051
11. Folli F, Sabowitz BN, Schwesinger W, Fanti P, Guardado-Mendoza R, Muscogiuri G. Bariatric surgery and bone disease: from clinical perspective to molecular insights. Int J Obes (Lond) (2012) 36(11):1373-9. doi:10.1038/ijo.2012.115
12. Ong T, Sahota O, Tan W, Marshall L. A United Kingdom perspective on the relationship between body mass index (BMI) and bone health: a cross sectional analysis of data from the Nottingham Fracture Liaison Service. Bone (2013) 59:207-10. doi:10.1016/j.bone.2013.11.024
13. Brzozowska MM, Sainsbury A, Eisman JA, Baldock PA, Center JR. Bariatric surgery, bone loss, obesity and possible mechanisms. Obes Rev (2013) 14(1):52-67. doi:10.1111/j.1467-789X.2012.01050.x
14. Leslie WD, Rubin MR, Schwartz AV, Kanis JA. Type 2 diabetes and bone. J Bone Miner Res (2012) 27(11):2231-7. doi:10.1002/jbmr.1759
15. Nakamura KM, Haglind EG, Clowes JA, Achenbach SJ, Atkinson EJ, Melton LJ III, et al. Fracture risk following bariatric surgery: a population-based study. Osteoporos Int (2014) 25(1):151-8. doi:10.1007/s00198-013-2463-x
16. Nielson CM, Srikanth P, Orwoll ES. Obesity and fracture in men and women: an epidemiologic perspective. J Bone Miner Res (2012) 27(1):1-10. doi:10.1002/jbmr.1486
17. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature (1998) 395(6704):763-70. doi:10.1038/27376
18. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature (1994) 372(6505):425-32. doi:10.1038/372425a0
19. Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol (2002) 175(2):405-15. doi:10.1677/joe.0.1750405
20. Maor G, Rochwerger M, Segev Y, Phillip M. Leptin acts as a growth factor on the chondrocytes of skeletal growth centers. J Bone Miner Res (2002) 17(6):1034-43. doi:10.1359/jbmr.2002.17.6.1034
21. Steppan CM, Crawford DT, Chidsey-Frink KL, Ke H, Swick AG. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept (2000) 92(1-3):73-8. doi:10.1016/S0167-0115(00)00152-X
22. Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology (1999) 140(4):1630-8. doi:10.1210/en.140.4.1630
23. Holloway WR, Collier FM, Aitken CJ, Myers DE, Hodge JM, Malakellis M, et al. Leptin inhibits osteoclast generation. J Bone Miner Res (2002) 17(2):200-9. doi:10.1359/jbmr.2002.17.2.200
24. Cornish J, Naot D, Costa JL. The bone-fat mass relationship: laboratory studies. IBMS BoneKey (2009) 6:311-22. doi:10.1138/20090395
25. Hamrick MW, Della-Fera MA, Choi YH, Pennington C, Hartzell D, Baile CA. Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice. J Bone Miner Res (2005) 20(6):994-1001. doi:10.1359/JBMR.050103
26. Williams GA, Callon KE, Watson M, Costa JL, Ding Y, Dickinson M, et al. Skeletal phenotype of the leptin receptor-deficient db/db mouse. J Bone Miner Res (2011) 26(8):1698-709. doi:10.1002/jbmr.367
27. Burguera B, Hofbauer LC, Thomas T, Gori F, Evans GL, Khosla S, et al. Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology (2001) 142(8):3546-53. doi:10.1210/en.142.8.3546
28. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell (2000) 100(2):197-207. doi:10.1016/S0092-8674(00)81558-5
29. Bartell SM, Rayalam S, Ambati S, Gaddam DR, Hartzell DL, Hamrick M, et al. Central (ICV) leptin injection increases bone formation, bone mineral density, muscle mass, serum IGF-1, and the expression of osteogenic genes in leptin-deficient ob/ob mice. J Bone Miner Res (2011) 26(8):1710-20. doi:10.1002/jbmr.406
30. Gimble JM. Leptin's balancing act between bone and fat. J Bone Miner Res (2011) 26(8):1694-7. doi:10.1002/jbmr.445
31. Blain H, Vuillemin A, Guillemin F, Durant R, Hanesse B, de Talance N, et al. Serum leptin level is a predictor of bone mineral density in postmenopausal women. J Clin Endocrinol Metab (2002) 87(3):1030-5. doi:10.1210/jc.87.3.1030
32. Thomas T, Burguera B, Melton LJ III, Atkinson EJ, O'Fallon WM, Riggs BL, et al. Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone (2001) 29(2):114-20. doi:10.1016/S8756-3282(01)00487-2
33. Mohiti-Ardekani J, Soleymani-Salehabadi H, Owlia MB, Mohiti A. Relationships between serum adipocyte hormones (adiponectin, leptin, resistin), bone mineral density and bone metabolic markers in osteoporosis patients. J Bone Miner Metab (2013). doi:10.1007/s00774-013-0511-4
34. Peng XD, Xie H, Zhao Q, Wu XP, Sun ZQ, Liao EY. Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men. Clin Chim Acta (2008) 387(1-2):31-5. doi:10.1016/j.cca.2007.08.012
35. Zhang H, Xie H, Zhao Q, Xie GQ, Wu XP, Liao EY, et al. Relationships between serum adiponectin, apelin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in post-menopausal Chinese women. J Endocrinol Invest (2010) 33(10):707-11. doi:10.3275/6886
36. Barbour KE, Zmuda JM, Boudreau R, Strotmeyer ES, Horwitz MJ, Evans RW, et al. Adipokines and the risk of fracture in older adults. J Bone Miner Res (2011) 26(7):1568-76. doi:10.1002/jbmr.361
37. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun (1999) 257(1):79-83. doi:10.1006/bbrc.1999.0255
38. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (1996) 120(4):803-12. doi:10.1093/oxfordjournals.jbchem.a021483
39. Wang Y, Lam KS, Chan L, Chan KW, Lam JB, Lam MC, et al. Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J Biol Chem (2006) 281(24):16391-400. doi:10.1074/jbc. M513907200
40. Ye R, Scherer PE. Adiponectin, driver or passenger on the road to insulin sensitivity? Mol Metab (2013) 2(3):133-41. doi:10.1016/j.molmet.2013.04.001
41. Jurimae J, Jurimae T, Ring-Dimitriou S, LeMura LM, Arciero PJ, von Duvillard SP. Plasma adiponectin and insulin sensitivity in overweight and normal-weight middle-aged premenopausal women. Metabolism (2009) 58(5):638-43. doi:10.1016/j.metabol.2008.12.009
42. Lenchik L, Register TC, Hsu FC, Lohman K, Nicklas BJ, Freedman BI, et al. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone (2003) 33(4):646-51. doi:10.1016/S8756-3282(03)00237-0
43. Richards JB, Valdes AM, Burling K, Perks UC, Spector TD. Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab (2007) 92(4):1517-23. doi:10.1210/jc.2006-2097
44. Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone (2004) 35(4):842-9. doi:10.1016/j.bone.2004.06.008
45. Shinoda Y, Yamaguchi M, Ogata N, Akune T, Kubota N, Yamauchi T, et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem (2006) 99(1):196-208. doi:10.1002/jcb.20890
46. Luo XH, Guo LJ, Yuan LQ, Xie H, Zhou HD, Wu XP, et al. Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res (2005) 309(1):99-109. doi:10.1016/j.yexcr.2005.05.021
47. Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun (2005) 331(2):520-6. doi:10.1016/j.bbrc.2005.03.210
48. Williams GA, Wang Y, Callon KE, Watson M, Lin JM, Lam JB, et al. In vitro and in vivo effects of adiponectin on bone. Endocrinology (2009) 150(8):3603-10. doi:10.1210/en.2008-1639
49. Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res (2006) 21(10):1648-56. doi:10.1359/jbmr.060707
50. Yamaguchi N, Kukita T, Li YJ, Kamio N, Fukumoto S, Nonaka K, et al. Adiponectin inhibits induction of TNF-alpha/RANKL-stimulated NFATc1 via the AMPK signaling. FEBS Lett (2008) 582(3):451-6. doi:10.1016/j.febslet.2007.12.037
51. Naot D, Williams GA, Lin JM, Cornish J, Grey A. Evidence that contamination by lipopolysaccharide confounds in vitro studies of adiponectin activity in bone. Endocrinology (2012) 153(5):2076-81. doi:10.1210/en.2011-2004
52. Turner JJ, Smolinska MJ, Sacre SM, Foxwell BM. Induction of TLR tolerance in human macrophages by adiponectin: does LPS play a role? Scand J Immunol (2009) 69(4):329-36. doi:10.1111/j.1365-3083.2008.02224.x
53. Yamaguchi N, Kukita T, Li YJ, Martinez Argueta JG, Saito T, Hanazawa S, et al. Adiponectin inhibits osteoclast formation stimulated by lipopolysaccharide from Actinobacillus actinomycetemcomitans. FEMS Immunol Med Microbiol (2007) 49(1):28-34. doi:10.1111/j.1574-695X.2006.00164.x
54. Kajimura D, Lee HW, Riley KJ, Arteaga-Solis E, Ferron M, Zhou B, et al. Adiponectin regulates bone mass via opposite central and peripheral mechanisms through FoxO1. Cell Metab (2013) 17(6):901-15. doi:10.1016/j.cmet.2013.04.009
55. Wang F, Wang PX, Wu XL, Dang SY, Chen Y, Ni YY, et al. Deficiency of adiponectin protects against ovariectomy-induced osteoporosis in mice. PLoS One (2013) 8(7):e68497. doi:10.1371/journal.pone.0068497
56. Magni P, Dozio E, Galliera E, Ruscica M, Corsi MM. Molecular aspects of adipokine-bone interactions. Curr Mol Med (2010) 10(6):522-32. doi:10.2174/156652410792231295
57. Sucunza N, Barahona MJ, Resmini E, Fernandez-Real JM, Ricart W, Farrerons J, et al. A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly. J Clin Endocrinol Metab (2009) 94(10):3889-96. doi:10.1210/jc.2009-0474
58. Biver E, Salliot C, Combescure C, Gossec L, Hardouin P, Legroux-Gerot I, et al. Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis. J Clin Endocrinol Metab (2011) 96(9):2703-13. doi:10.1210/jc.2011-0047
59. Ge H, Yang G, Huang L, Motola DL, Pourbahrami T, Li C. Oligomerization and regulated proteolytic processing of angiopoietin-like protein 4. J Biol Chem (2004) 279(3):2038-45. doi:10.1074/jbc. M307583200
60. Kersten S, Mandard S, Tan NS, Escher P, Metzger D, Chambon P, et al. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem (2000) 275(37):28488-93. doi:10.1074/jbc. M004029200
61. Lin JM, Naot D, Watson M, Costa JL, Reid IR, Cornish J, et al. Skeletal actions of fasting-induced adipose factor (FIAF). Endocrinology (2013) 154(12):4685-94. doi:10.1210/en.2013-1238
62. Thommesen L, Stunes AK, Monjo M, Grosvik K, Tamburstuen MV, Kjobli E, et al. Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem (2006) 99(3):824-34. doi:10.1002/jcb.20915
63. Xie H, Tang SY, Luo XH, Huang J, Cui RR, Yuan LQ, et al. Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int (2007) 80(3):201-10. doi:10.1007/s00223-006-0155-7
64. Abrahamsen B, Rohold A, Henriksen JE, Beck-Nielsen H. Correlations between insulin sensitivity and bone mineral density in non-diabetic men. Diabet Med (2000) 17(2):124-9. doi:10.1046/j.1464-5491.2000.00234.x
65. Ahmed LA, Schirmer H, Berntsen GK, Fonnebo V, Joakimsen RM. Features of the metabolic syndrome and the risk of non-vertebral fractures: the Tromso study. Osteoporos Int (2006) 17(3):426-32. doi:10.1007/s00198-005-0003-z
66. Reid IR, Ames R, Evans MC, Sharpe S, Gamble G, France JT, et al. Determinants of total body and regional bone mineral density in normal postmenopausal women - a key role for fat mass. J Clin Endocrinol Metab (1992) 75(1):45-51. doi:10.1210/jc.75.3.779
67. Reid IR, Evans MC, Cooper GJ, Ames RW, Stapleton J. Circulating insulin levels are related to bone density in normal postmenopausal women. Am J Physiol (1993) 265(4 Pt 1):E655-9.
68. Stolk RP, Van Daele PL, Pols HA, Burger H, Hofman A, Birkenhager JC, et al. Hyperinsulinemia and bone mineral density in an elderly population: the Rotterdam study. Bone (1996) 18(6):545-9. doi:10.1016/8756-3282(96)00079-8
69. Hickman J, McElduffA. Insulin promotes growth of the cultured rat osteosarcoma cell line UMR-106-01: an osteoblast-like cell. Endocrinology (1989) 124(2):701-6. doi:10.1210/endo-124-2-701
70. Pun KK, Lau P, Ho PW. The characterization, regulation, and function of insulin receptors on osteoblast-like clonal osteosarcoma cell line. J Bone Miner Res (1989) 4(6):853-62. doi:10.1002/jbmr.5650040610
71. Cornish J, Callon KE, Reid IR. Insulin increases histomorphometric indices of bone formation in vivo. Calcif Tissue Int (1996) 59(6):492-5. doi:10.1007/BF00369216
72. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA (2008) 105(13):5266-70. doi:10.1073/pnas.0711119105
73. Fulzele K, Riddle RC, DiGirolamo DJ, Cao X, Wan C, Chen D, et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell (2010) 142(2):309-19. doi:10.1016/j.cell.2010.06.002
74. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell (2007) 130(3):456-69. doi:10.1016/j.cell.2007.05.047
75. Lee GS, Simpson C, Sun BH, Yao C, Foer D, Sullivan B, et al. Measurement of plasma, serum, and platelet serotonin in individuals with high bone mass and mutations in LRP5. J Bone Miner Res (2014) 29(4):976-81. doi:10.1002/jbmr.2086
76. Schwartz AV, Schafer AL, Grey A, VittinghoffE, Palermo L, Lui LY, et al. Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials. J Bone Miner Res (2013) 28(6):1348-54. doi:10.1002/jbmr.1865
77. Cornish J, Callon KE, Cooper GJ, Reid IR. Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. Biochem Biophys Res Commun (1995) 207(1):133-9. doi:10.1006/bbrc.1995.1163
78. Cornish J, Callon KE, Bava U, Kamona SA, Cooper GJ, Reid IR. Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. Bone (2001) 29(2):162-8. doi:10.1016/S8756-3282(01)00494-X
79. Cornish J, Callon KE, King AR, Cooper GJ, Reid IR. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am J Physiol (1998) 275(4 Pt 1):E694-9.
80. Horcajada-Molteni MN, Chanteranne B, Lebecque P, Davicco MJ, Coxam V, Young A, et al. Amylin and bone metabolism in streptozotocin-induced diabetic rats. J Bone Miner Res (2001) 16(5):958-65. doi:10.1359/jbmr.2001.16.5.958
81. Horcajada-Molteni MN, Davicco MJ, Lebecque P, Coxam V, Young AA, Barlet JP. Amylin inhibits ovariectomy-induced bone loss in rats. J Endocrinol (2000) 165(3):663-8. doi:10.1677/joe.0.1650663
82. Gutierrez-Rojas I, Lozano D, Nuche-Berenguer B, Moreno P, Acitores A, Ramos-Alvarez I, et al. Amylin exerts osteogenic actions with different efficacy depending on the diabetic status. Mol Cell Endocrinol (2013) 365(2):309-15. doi:10.1016/j.mce.2012.11.013
83. Dacquin R, Davey RA, Laplace C, Levasseur R, Morris HA, Goldring SR, et al. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol (2004) 164(4):509-14. doi:10.1083/jcb.200312135
84. Davey RA, Moore AJ, Chiu MW, Notini AJ, Morris HA, Zajac JD. Effects of amylin deficiency on trabecular bone in young mice are sex-dependent. Calcif Tissue Int (2006) 78(6):398-403. doi:10.1007/s00223-005-0286-2
85. Wojcik MH, Meenaghan E, Lawson EA, Misra M, Klibanski A, Miller KK. Reduced amylin levels are associated with low bone mineral density in women with anorexia nervosa. Bone (2010) 46(3):796-800. doi:10.1016/j.bone.2009.11.014
86. Borm AK, Klevesath MS, Borcea V, Kasperk C, Seibel MJ, Wahl P, et al. The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus. Horm Metab Res (1999) 31(8):472-5. doi:10.1055/s-2007-978777
87. Buchanan CM, Phillips AR, Cooper GJ. Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet beta-cells and enhances insulin secretion. Biochem J (2001) 360(Pt 2):431-9. doi:10.1042/0264-6021:3600431
88. Yang G, Li L, Chen W, Liu H, Boden G, Li K. Circulating preptin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Ann Med (2009) 41(1):52-6. doi:10.1080/07853890802244142
89. Cornish J, Callon KE, Bava U, Watson M, Xu X, Lin JM, et al. Preptin, another peptide product of the pancreatic beta-cell, is osteogenic in vitro and in vivo. Am J Physiol (2007) 292(1):E117-22. doi:10.1152/ajpendo.00642.2005
90. Liu YS, Lu Y, Liu W, Xie H, Luo XH, Wu XP, et al. Connective tissue growth factor is a downstream mediator for preptin-induced proliferation and differentiation in human osteoblasts. Amino Acids (2010) 38(3):763-9. doi:10.1007/s00726-009-0281-4
91. Bosetti M, Sabbatini M, Nicoli E, Fusaro L, Cannas M. Effects and differentiation activity of IGF-I, IGF-II, insulin and preptin on human primary bone cells. Growth Factors (2013) 31(2):57-65. doi:10.3109/08977194.2013.770392
92. Khosla S, Ballard FJ, Conover CA. Use of site-specific antibodies to characterize the circulating form of big insulin-like growth factor II in patients with hepatitis C-associated osteosclerosis. J Clin Endocrinol Metab (2002) 87(8):3867-70. doi:10.1210/jcem.87.8.8783
93. Li N, Zheng YB, Han J, Liang W, Wang JY, Zhou JR, et al. Lower circulating preptin levels in male patients with osteoporosis are correlated with bone mineral density and bone formation. BMC Musculoskelet Disord (2013) 14:49. doi:10.1186/1471-2474-14-49
94. Walsh JS, Henriksen DB. Feeding and bone. Arch Biochem Biophys (2010) 503(1):11-9. doi:10.1016/j.abb.2010.06.020
95. Wong IP, Baldock PA, Herzog H. Gastrointestinal peptides and bone health. Curr Opin Endocrinol Diabetes Obes (2010) 17(1):44-50. doi:10.1097/MED.0b013e3283344a05
96. Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone (2002) 30(6):886-90. doi:10.1016/S8756-3282(02)00728-7
97. Ihle R, Loucks AB. Dose-response relationships between energy availability and bone turnover in young exercising women. J Bone Miner Res (2004) 19(8):1231-40. doi:10.1359/JBMR.040410
98. Dornonville de la Cour C, Bjorkqvist M, Sandvik AK, Bakke I, Zhao CM, Chen D, et al. A-like cells in the rat stomach contain ghrelin and do not operate under gastrin control. Regul Pept (2001) 99(2-3):141-50. doi:10.1016/S0167-0115(01)00243-9
99. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature (2000) 407(6806):908-13. doi:10.1038/35038090
100. Costa JL, Naot D, Lin JM, Watson M, Callon KE, Reid IR, et al. Ghrelin is an osteoblast mitogen and increases osteoclastic bone resorption in vitro. Int J Pept (2011) 2011:605193. doi:10.1155/2011/605193
101. Delhanty PJ, van der Eerden BC, van der Velde M, Gauna C, Pols HA, Jahr H, et al. Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a. J Endocrinol (2006) 188(1):37-47. doi:10.1677/joe.1.06404
102. Fukushima N, Hanada R, Teranishi H, Fukue Y, Tachibana T, Ishikawa H, et al. Ghrelin directly regulates bone formation. J Bone Miner Res (2005) 20(5):790-8. doi:10.1359/JBMR.041237
103. Kim SW, Her SJ, Park SJ, Kim D, Park KS, Lee HK, et al. Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells. Bone (2005) 37(3):359-69. doi:10.1016/j.bone.2005.04.020
104. MacCarinelli G, Sibilia V, Torsello A, Raimondo F, Pitto M, Giustina A, et al. Ghrelin regulates proliferation and differentiation of osteoblastic cells. J Endocrinol (2005) 184(1):249-56. doi:10.1677/joe.1.05837
105. Wang DH, Hu YS, Du JJ, Hu YY, Zhong WD, Qin WJ. Ghrelin stimulates proliferation of human osteoblastic TE85 cells via NO/cGMP signaling pathway. Endocrine (2009) 35(1):112-7. doi:10.1007/s12020-008-9117-3
106. Sun Y, Ahmed S, Smith RG. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol (2003) 23(22):7973-81. doi:10.1128/MCB.23.22.7973-7981.2003
107. Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA (2004) 101(13):4679-84. doi:10.1073/pnas.0305930101
108. Bewick GA, Kent A, Campbell D, Patterson M, Ghatei MA, Bloom SR, et al. Mice with hyperghrelinemia are hyperphagic and glucose intolerant and have reduced leptin sensitivity. Diabetes (2009) 58(4):840-6. doi:10.2337/db08-1428
109. Huda MS, Durham BH, Wong SP, Dovey TM, McCulloch P, Kerrigan D, et al. Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects. Bone (2007) 41(3):406-13. doi:10.1016/j.bone.2007.05.006
110. Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med (2008) 149(9):601-11. doi:10.7326/0003-4819-149-9-200811040-00003
111. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B. Gastric inhibitory polypeptide: the neglected incretin revisited. Regul Pept (2002) 107(1-3):1-13. doi:10.1016/S0167-0115(02)00039-3
112. Bollag RJ, Zhong Q, Ding KH, Phillips P, Zhong L, Qin F, et al. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol Cell Endocrinol (2001) 177(1-2):35-41. doi:10.1016/S0303-7207(01)00405-1
113. Bollag RJ, Zhong Q, Phillips P, Min L, Zhong L, Cameron R, et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology (2000) 141(3):1228-35. doi:10.1210/endo.141.3.7366
114. Zhong Q, Itokawa T, Sridhar S, Ding KH, Xie D, Kang B, et al. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Am J Physiol Metab (2007) 292(2):E543-8. doi:10.1152/ajpendo.00364.2006
115. Ding KH, Shi XM, Zhong Q, Kang B, Xie D, Bollag WB, et al. Impact of glucose-dependent insulinotropic peptide on age-induced bone loss. J Bone Miner Res (2008) 23(4):536-43. doi:10.1359/jbmr.071202
116. Xie D, Zhong Q, Ding KH, Cheng H, Williams S, Correa D, et al. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone (2007) 40(5):1352-60. doi:10.1016/j.bone.2007.01.007
117. Tsukiyama K, Yamada Y, Yamada C, Harada N, Kawasaki Y, Ogura M, et al. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Mol Endocrinol (2006) 20(7):1644-51. doi:10.1210/me.2005-0187
118. Xie D, Cheng H, Hamrick M, Zhong Q, Ding KH, Correa D, et al. Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone (2005) 37(6):759-69. doi:10.1016/j.bone.2005.06.021
119. Henriksen DB, Alexandersen P, Bjarnason NH, Vilsboll T, Hartmann B, Henriksen EE, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res (2003) 18(12):2180-9. doi:10.1359/jbmr.2003.18.12.2180
120. Cho YM, Wideman RD, Kieffer TJ. Clinical application of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus. Endocrinol Metab (Seoul) (2013) 28(4):262-74. doi:10.3803/EnM.2013.28.4.262
121. Trautvetter U, Jahreis G. Effect of supplementary calcium phosphate on plasma gastrointestinal hormones in a double-blind, placebo-controlled, cross-over human study. Br J Nutr (2014) 111(2):287-93. doi:10.1017/S0007114513002341
122. Pacheco-Pantoja EL, Ranganath LR, Gallagher JA, Wilson PJ, Fraser WD. Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol (2011) 11:12. doi:10.1186/1472-6793-11-12
123. Sanz C, Vazquez P, Blazquez C, Barrio PA, Alvarez Mdel M, Blazquez E. Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow. Am J Physiol (2010) 298(3):E634-43. doi:10.1152/ajpendo.00460.2009
124. Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology (2008) 149(2):574-9. doi:10.1210/en.2007-1292
125. Karsdal MA, Holst JJ, Henriksen D. GLP-2 reduces bone resorption in vitro via the osteoclast GLP-2 receptor. J Bone Miner Res (2004) 19(S1):S416. doi:10.1002/jbmr.5650191306
126. Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, et al. Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. Bone (2007) 40(3):723-9. doi:10.1016/j.bone.2006.09.025
127. Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone (2009) 45(5):833-42. doi:10.1016/j.bone.2009.07.008